GSK has signed a sales contract with GC Pharma & Kwang Dong

for Shingrix

Strategic partnerships enhance expertise in the distribution of shingles vaccines

GSK has signed a joint sales contract with two domestic companies, GC Pharma and Kwang Dong, to sell the shingles vaccine Shingrix.

 

GSK Korea announced on the 24th that it signed a Co-Promotion and Distribution Partnership for Shingrix's domestic sales and marketing on the 21st.

 

Through this partnership, GC Pharma and Kwang Dong will jointly promote GSK's new shingles vaccine Shingrix on all distribution channels, including hospitals.

 

GSK subsidiary is expected to strengthen its expertise in the distribution of shingles vaccines by selecting GC Pharma and Kwang Dong, which have domestic sales networks and marketing know-how accumulated in the shingles vaccine sector.

 

"We are pleased to introduce a shingles prevention vaccine for adults over 50 and those over 18 years of age through a strategic partnership with GC Pharma and Kwang Dong, which have expertise in vaccine distribution," GSK President Rob Kempton said.

 

Heo Eun-cheol, CEO of GC Pharma, said, "We are very happy to partner with GSK, a leading global healthcare company.

 

Based on GC Pharma's accumulated vaccine know-how and understanding of distribution, we will work closely with GSK to provide better shingles prevention options to more people, he said.

 

Choi Sung-won, CEO of Kwang Dong, said, "Kwang Dong has achieved various achievements for a wide range of patients and medical staff through partnerships with various domestic and foreign companies." "We will contribute to the health of the people by focusing on Shingrix the professional capabilities that GSK has developed as a vaccine distribution and marketing partner since 2015," he stressed.

 

Meanwhile, Shingrix is scheduled to be released in Korea in December.